（原标题：A股上市后首次 百济神州实现半年度业绩盈利） 得益于在中国获批新适应症纳入医保所带来的新增患者需求以及药品进院数量的增加，上半年百泽安的销售额总计26.43亿元，同比增长20.6%。 证券时报记者 张一帆 8月6日，百济神州（688235）披露业绩，2025年上半年实现净利润4.5亿元，A股上市后首次实现半年度业绩盈利。公司同步上调全年营收预计区 间下限，并将预期毛利率上调至"80%至90%的中高位区间"。受此影响，百济神州美股盘前交易上涨逾4%。 财报显示，2025年上半年百济神州营业总收入175.18亿元，同比上升46%；归母净利润4.5亿元，扣非后净利润2.61亿元，均实现同比扭亏为盈。 公司第二季度业绩表现略高于市场预期。今年一季度，百济神州首次实现GAAP（通用会计制度）下的季度盈利，A股财务数据中归母净利润 为-0.95亿元。 "第二季度强劲的表现，进一步巩固了公司在全球肿瘤治疗领域的领先地位，并充分证明了我们实现可持续、长期增长的能力。"百济神州联合创 始人、董事长兼首席执行官欧雷强表示。 据悉，百济神州上半年收入的增长主要得益于公司自研产品百悦泽（泽布替尼胶囊）和安进授权产品以及百泽 ...

Group 1 - The company has adjusted its 2025 annual operating performance forecast to provide investors with a clearer understanding of its business performance and future prospects [1][2] - The adjustment in expected operating income is primarily attributed to the leading position of Baiyueze in the US market and its continued expansion in Europe and other key global markets [3] Group 2 - For the first half of 2025, the company's product revenue reached 17.36 billion RMB, a year-on-year increase of 45.8%, while total operating revenue was 17.52 billion RMB, up 46.0% from the previous year [9] - The net profit attributable to the parent company for the first half of 2025 was 450 million RMB, with total assets at 44.87 billion RMB, an increase of 4.8% from the beginning of the period [9][19] - Baiyueze's global sales totaled 12.53 billion RMB in the first half of 2025, representing a year-on-year growth of 56.2%, with US sales at 8.96 billion RMB, up 51.7% [10][11] Group 3 - Baiyueze is the only BTK inhibitor with flexible dosing options, and it has been approved in 75 markets globally, with ongoing clinical trials in over 30 countries [12] - The company is also advancing its next-generation pipeline products and emphasizes a rapid concept verification strategy in its global clinical development [14] - The company has a significant presence in the oncology research field, with a large team dedicated to small molecule and antibody drug discovery [14] Group 4 - The company has initiated several key clinical trials for its products, including the global phase III trial for Sonrotoclax in combination with Baiyueze for CLL patients [15][16] - The company plans to launch multiple clinical trials for various cancer treatments in the coming years, including trials for breast cancer and lung cancer [17]

Core Insights - Company achieved its first half-year profit with a net profit of 450 million RMB, reversing a loss of 2.877 billion RMB in the same period last year [1] - Total revenue for the first half of 2025 reached 17.518 billion RMB, a year-on-year increase of 46.0%, with core product revenue at 17.360 billion RMB, up 45.8% [1][2] - The company’s flagship product, Baiyueze (Zebutinib), generated global sales of 12.527 billion RMB, marking a 56.2% increase, with significant growth in the U.S. and European markets [2] Financial Performance - The second quarter revenue was approximately 9.4 billion RMB, reflecting a 42% year-on-year growth [1] - GAAP net profit for the second quarter was about 680 million RMB, indicating strong profitability momentum [1] - The company raised its full-year revenue guidance from a range of 35.2 billion to 38.1 billion RMB to 35.8 billion to 38.1 billion RMB, reflecting management's confidence in future growth [4][5] Product Performance - Baiyueze's sales in the U.S. reached 8.958 billion RMB, a 51.7% increase, while sales in Europe grew by 81.4% [2] - Another key product, Baizean (Tislelizumab), achieved sales of 2.643 billion RMB, a 20.6% increase, benefiting from new indications and increased patient demand [2][4] - Baizean has been approved in 47 global markets, with significant recent approvals in key markets like Japan and Europe [4] Strategic Developments - The company is advancing its next-generation innovation pipeline, with two blood cancer products in Phase 3 clinical trials expected to announce key data soon [4] - Over the next 18 months, the company anticipates more than 20 research milestones, including progress in its solid tumor pipeline [4] - The ongoing expansion of the global commercialization network and continuous approval of new indications for core products are positioning the company as a leading biopharmaceutical enterprise [5]

Major Events - Cathay Pacific (00293) has purchased fourteen Boeing 777-9 aircraft [1] - Hengrui Medicine (01276) received FDA orphan drug designation for the combination of injection Rituximab and chemotherapy for gastric cancer or gastroesophageal junction adenocarcinoma [1] - China National Pharmaceutical Group's self-developed drug TQ05105 (JAK/ROCK inhibitor) has been included in the breakthrough therapy designation program [1] - Junshi Biosciences (02696) completed the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanli Kang® for active glomerulonephritis in China [1] - YingTai Medical (01501) plans to invest no more than 110 million yuan to establish the Huai Ge Guang Tai Fund [1] - JinJing New Energy (01783) proposed a stock split [1] Financial Data - Cathay Pacific (00293) reported a mid-term profit attributable to shareholders of 3.651 billion HKD, a year-on-year increase of 1.1%, with an interim dividend of 0.20 HKD per share [1] - Uni-President Enterprises China (00220) reported a mid-term profit attributable to shareholders of 1.287 billion CNY, a year-on-year increase of 33.24% [1] - BeiGene (06160) reported a net profit of 94.32 million USD for the second quarter, returning to profitability year-on-year [1] - Sun Hung Kai Properties (00086) issued a profit warning, expecting mid-term profit attributable to shareholders to increase to no less than 800 million HKD year-on-year [1] - Weixin Jinke (02003) issued a profit warning, expecting mid-term comprehensive net profit to be no less than 200 million CNY, a significant year-on-year increase [1] - ZhiZi Cheng Technology (09911) issued a profit warning, expecting mid-term profit attributable to shareholders to increase by approximately 108.9% to 126.7% year-on-year [1] - China Star Optoelectronics (00334) issued a profit warning, expecting a year-on-year increase of no less than 600% in profit attributable to the parent company for the first half of the year [1] - Xinli International (00732) reported a total operating revenue of approximately 1.468 billion HKD in July, a year-on-year decrease of about 3.3% [1]

Core Viewpoint - The company, BeiGene, reported significant growth in its financial performance for the first half of 2025, with total revenue reaching RMB 17.52 billion, a 46% increase year-over-year, driven by strong sales of its proprietary products and collaborations [1][6]. Financial Performance - Total revenue for the first half of 2025 was RMB 17,518,269, compared to RMB 11,996,406 in the same period last year, marking a 46.0% increase [1]. - Product revenue accounted for RMB 17,360,163, up 45.8% from RMB 11,907,783 year-over-year [1]. - The company achieved a net profit attributable to shareholders of RMB 261,105, a significant recovery from a net loss of RMB 3,124,740 in the previous year [1]. - Basic earnings per share improved to RMB 0.32 from a loss of RMB 2.12 [1]. - Total assets increased by 4.8% to RMB 44,872,354, while equity attributable to shareholders rose by 11.1% to RMB 26,856,000 [1]. Product Performance - The growth in product revenue was primarily driven by the sales of the self-developed drug, Brukinsa (Zebutinib), and the licensed product from Amgen, as well as the sales of Tislelizumab (百泽安) [1][6]. - Sales in the U.S. reached RMB 8.96 billion, a 51.7% increase, attributed to strong demand across all indications and favorable net pricing [1]. - European sales totaled RMB 1.92 billion, up 81.4%, due to increased market share in major European markets [1]. - In China, sales reached RMB 1.19 billion, a 36.5% increase, driven by new indications being included in medical insurance [1]. Clinical Development - The company is advancing its pipeline with a focus on rapid clinical concept validation, supported by a global R&D team of over 3,700 [3]. - The company has the largest oncology research team in the industry and is working on multiple innovative platforms, including antibody-drug conjugates and multi-specific antibodies [3]. - Key clinical trials are ongoing for drugs like Sonrotoclax and BGB-16673, with plans for significant milestones in the next 18 months [4][5]. Corporate Developments - The company has officially changed its English name to BeOne Medicines Ltd. and relocated its registered office from the Cayman Islands to Switzerland [6].

A 股代码：688235 A 股简称：百济神州 公告编号：2025-029 港股代码：06160 港股简称：百济神州 美股代码：ONC 百济神州有限公司 自愿披露关于2025年度经营业绩预测调整的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 百济神州有限公司（以下简称"公司"）于 2025 年 2 月 28 日披露了《百 济神州有限公司自愿披露关于 2025 年度经营业绩预测的公告》（公告编号： 公司经营业绩情况和未来业绩前景，公司决定对 2025 年度经营业绩预测情况进 行调整，现将有关情况公告如下： 一、2025 年度经营业绩预测调整情况 综合公司业务发展趋势，公司对预计的中国企业会计准则下 2025 年全年的 经营业绩情况调整如下： 调整前 2025 年度经营业绩预 调整后 2025 年度经营业绩预 测 测 将介于人民币 352 亿元至 381 将介于人民币 358 亿元至 381 营业收入 亿元之间 亿元之间 研发费用、销售及管理费 将介于人民币 295 亿元至 319 将介于人民币 295 亿元至 319 ...

Major Events - Cathay Pacific (00293) has purchased fourteen Boeing 777-9 aircraft [1] - Hengrui Medicine (01276) received FDA orphan drug designation for the combination of injection Rituximab and chemotherapy for gastric cancer or gastroesophageal junction adenocarcinoma [1] - China National Pharmaceutical Group (01177) has its self-developed drug TQ05105 (JAK/ROCK inhibitor) included in the breakthrough therapy designation program [1] - Junshi Biosciences (02696) completed the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanli Kang® for active glomerulonephritis in China [1] - YingTai Medical (01501) plans to invest no more than 110 million yuan to establish the Huai Ge Guang Tai Fund [1] - JinJing New Energy (01783) proposed a stock split [1] Financial Data - Cathay Pacific (00293) reported a mid-term profit attributable to shareholders of 3.651 billion HKD, a year-on-year increase of 1.1%, with an interim dividend of 0.2 HKD per share [1] - Uni-President Enterprises China (00220) reported a mid-term profit attributable to shareholders of 1.287 billion CNY, a year-on-year increase of 33.24% [1] - BeiGene (06160) reported a net profit of 94.32 million USD in the second quarter, returning to profitability year-on-year [1] - New World Development Company (00086) issued a profit warning, expecting mid-term profit attributable to shareholders to increase to no less than 800 million HKD year-on-year [1] - Weixin Jinkao (02003) issued a profit warning, expecting mid-term comprehensive net profit to be no less than 200 million CNY, a significant year-on-year increase [1] - ZhiZi Cheng Technology (09911) issued a profit warning, expecting mid-term profit attributable to shareholders to increase by approximately 108.9% to 126.7% year-on-year [1] - Huaxian Optoelectronics (00334) issued a profit warning, expecting a year-on-year increase of no less than 600% in profit attributable to the parent company [1] - Xinli International (00732) reported a total operating revenue of approximately 1.468 billion HKD in July, a year-on-year decrease of about 3.3% [1]

Group 1 - BeiGene reported a net profit of 450 million yuan for the first half of 2025, reversing a loss of 287.7 million yuan in the same period last year, with a total revenue of 17.518 billion yuan, up 46.0% year-on-year [1] - The company attributed the profit increase to significant growth in product revenue and improved operational efficiency through cost management [1] Group 2 - Tianyang Technology is planning to acquire a portion of the equity in Tonglian Financial Services Co., Ltd. and related companies, aiming to enhance its competitive advantage in credit card and consumer finance system services [2] - The acquisition is expected to create synergies in areas such as industry positioning, product development, and technical services [2] Group 3 - ST Yazhen's stock experienced abnormal trading fluctuations, with a cumulative price increase of 12% over three consecutive trading days, leading to a suspension of trading for investigation starting August 7, 2025 [3] - The company noted that the short-term price increase significantly deviated from the Shanghai Composite Index and the furniture manufacturing industry [3] Group 4 - Shunbo Alloy reported a revenue of approximately 7.126 billion yuan for the first half of 2025, an increase of 11.75% year-on-year, with a net profit of about 176.6 million yuan, up 110.56% [4] - Tapa Group achieved a revenue of approximately 2.056 billion yuan, a 4.05% increase year-on-year, with a net profit of about 435.4 million yuan, up 92.47% [4] - Liyuan Information reported a revenue of approximately 4.034 billion yuan, a 17.46% increase year-on-year, with a net profit of about 96.1 million yuan, up 65.79% [5] Group 5 - Zhongchumei reported a revenue of approximately 461.1 million yuan for the first half of 2025, a 16.46% increase year-on-year, with a net profit of about 126.8 million yuan, up 31.52% [5] - Pudong Development Bank reported a revenue of approximately 90.559 billion yuan, a 2.62% increase year-on-year, with a net profit of about 29.737 billion yuan, up 10.19% [5]

Core Viewpoint - BeiGene has reported its first half-year profitability since its listing, driven by significant product revenue growth and improved cost management [1][3]. Financial Performance - Total revenue for the first half of 2025 reached RMB 17.518 billion, a year-on-year increase of 46.0% [1]. - Operating profit was RMB 799 million, and net profit attributable to shareholders was RMB 450 million, marking a turnaround from losses in the previous year [1]. - Product revenue amounted to RMB 17.36 billion, up 45.8% year-on-year [1]. Key Products and Sales - The sales of the BTK inhibitor, Zebrutinib, reached RMB 12.527 billion in the first half, a 56.2% increase [2]. - In the U.S. market, Zebrutinib sales were RMB 8.958 billion, growing by 51.7% [1][2]. - The PD-1 inhibitor, Tislelizumab, generated sales of RMB 2.643 billion, reflecting a 20.6% increase [2]. Market Position - Zebrutinib has maintained the top position in the BTK inhibitor market in the U.S. for two consecutive quarters, with Q2 sales of USD 684 million, a 43% increase [2]. - In Europe, Zebrutinib sales reached RMB 1.918 billion, up 81.4% [2]. - In China, Zebrutinib sales were RMB 1.192 billion, a 36.5% increase [2]. R&D Pipeline - The company anticipates over 20 milestone developments in its blood cancer and solid tumor pipelines within the next 18 months [1]. - BeiGene has established three proprietary products in blood cancer treatment, including Zebrutinib and two products in Phase 3 clinical trials [3]. - The company is expanding its pipeline in solid tumors, focusing on various cancers and utilizing diverse technology platforms [3]. Future Guidance - BeiGene has updated its full-year revenue guidance for 2025 to a range of RMB 35.8 billion to RMB 38.1 billion [3]. - The gross margin guidance has been adjusted to a mid-high range of 80% to 90% [3]. - Positive cash flow from operating activities is expected for the year, excluding capital expenditures [3].

Major Events - Cathay Pacific (00293) has purchased fourteen Boeing 777-9 aircraft [1] - Hengrui Medicine (01276) received FDA orphan drug designation for injection of Rukang Qutuzumab combined with Atezolizumab and chemotherapy for gastric cancer or gastroesophageal junction adenocarcinoma [1] - China National Pharmaceutical Group (01177) has its self-developed TQ05105 (JAK/ROCK inhibitor) included in the breakthrough therapy designation program [1] - Junshi Biosciences (02696) completed the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanlikang® for active glomerulonephritis in China [1] - YingTai Medical (01501) plans to invest no more than 110 million yuan to establish the Huai Ge Guang Tai Fund [1] - JinJing New Energy (01783) proposed a stock split [1] Financial Data - Cathay Pacific (00293) reported a mid-term profit attributable to shareholders of 3.651 billion HKD, a year-on-year increase of 1.1%, with an interim dividend of 0.20 HKD per share [1] - Uni-President Enterprises China (00220) reported a mid-term profit attributable to shareholders of 1.287 billion CNY, a year-on-year increase of 33.24% [1] - BeiGene (06160) reported a net profit of 94.32 million USD for the second quarter, returning to profitability year-on-year [1] - Sun Hung Kai Properties (00086) issued a profit warning, expecting mid-term profit attributable to shareholders to increase to no less than 800 million HKD year-on-year [1] - Weimeng Jin Ke (02003) issued a profit warning, expecting mid-term comprehensive net profit to be no less than 200 million CNY, a significant year-on-year increase [1] - Zhi Zi Cheng Technology (09911) issued a profit warning, expecting mid-term profit attributable to shareholders to increase by approximately 108.9% to 126.7% year-on-year [1] - China Star Optoelectronics Technology (00334) issued a profit warning, expecting a year-on-year increase of no less than 600% in profit attributable to the parent company for the first half of the year [1] - Xinli International (00732) reported a total operating revenue of approximately 1.468 billion HKD in July, a year-on-year decrease of about 3.3% [1]